Quick Answer
GALECTIN THERAPEUTICS INC reported Total Assets of $19.53 million for the year ending 2025.
- GALECTIN THERAPEUTICS INC showed an increase of +11.6% in Total Assets from 2024 to 2025.
- This data is from GALECTIN THERAPEUTICS INC's annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2011: $8.16 million | Q3 2011: $8.10 million | Q1 2012: $15.54 million | Q2 2012: $13.32 million | Q3 2012: $11.19 million | Q1 2013: $7.20 million | Q2 2013: $5.23 million | Q3 2013: $9.78 million | Q1 2014: $36.90 million | Q2 2014: $34.59 million | Q3 2014: $31.32 million | Q1 2015: $29.97 million | Q2 2015: $26.68 million | Q3 2015: $21.51 million | Q1 2016: $22.79 million | Q2 2016: $18.25 million | Q3 2016: $16.12 million | Q1 2017: $14.00 million | Q2 2017: $9.33 million | Q3 2017: $7.01 million | Q1 2018: $4.93 million | Q2 2018: $11.21 million | Q3 2018: $10.62 million | Q1 2019: $7.83 million | Q2 2019: $53.01 million | Q3 2019: $50.76 million | Q1 2020: $44.11 million | Q2 2020: $41.32 million | Q3 2020: $34.05 million | Q1 2021: $22.90 million | Q2 2021: $33.41 million | Q3 2021: $38.04 million | Q1 2022: $33.62 million | Q2 2022: $25.89 million | Q3 2022: $17.91 million | Q1 2023: $20.23 million | Q2 2023: $20.08 million | Q3 2023: $22.16 million | Q1 2024: $25.89 million | Q2 2024: $27.66 million | Q3 2024: $28.97 million | Q1 2025: $9.53 million | Q2 2025: $15.60 million | Q3 2025: $12.87 million.
- Over the full 16 years of available data (2010 to 2025), GALECTIN THERAPEUTICS INC's Total Assets has grown by 210.0%.
- Historical annual values: Fiscal year 2025: $19.53 million | Fiscal year 2024: $17.50 million | Fiscal year 2023: $28.20 million | Fiscal year 2022: $21.29 million | Fiscal year 2021: $41.83 million | Fiscal year 2020: $29.60 million | Fiscal year 2019: $48.47 million | Fiscal year 2018: $9.01 million | Fiscal year 2017: $4.16 million | Fiscal year 2016: $15.80 million | Fiscal year 2015: $26.41 million | Fiscal year 2014: $29.68 million | Fiscal year 2013: $10.71 million | Fiscal year 2012: $9.56 million | Fiscal year 2011: $6.61 million | Fiscal year 2010: $6.30 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: